Brain dopamine transporter: gender differences and effect of chronic haloperidol

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Dopamine transporter (DAT) plays a crucial role in regulating dopaminergic neurotransmission.
• Gender differences in DAT expression and their implications are not fully understood.
• Haloperidol, an antipsychotic, affects dopamine system function.

Purpose of the Study:

• To investigate gender differences in rat brain dopamine transporter density and mRNA levels.
• To examine the effects of chronic haloperidol administration on DAT and D2 receptor binding.
• To correlate changes in DAT with dopamine clearance rates.

Main Methods:

• Quantification of striatal DAT sites using [3H]GBR 12935 radioligand binding.
• Measurement of substantia nigra DAT mRNA levels via in situ hybridization.
• Assessment of striatal D2 receptor binding using [3H]spiperone.

Main Results:

• Female rats showed significantly higher striatal DAT density and substantia nigra DAT mRNA levels compared to males.
• Chronic haloperidol treatment increased striatal D2 receptor binding but did not affect DAT binding or mRNA levels.
• These findings suggest that haloperidol-induced alterations in dopamine clearance may occur independently of changes in DAT expression or binding.

Conclusions:

• Gender influences dopamine transporter expression in the rat brain.
• Chronic haloperidol treatment impacts D2 receptor binding but not DAT density or gene expression.
• Dopamine clearance changes after haloperidol may not be mediated by alterations in the dopamine transporter itself.